Human amniotic fluid preparation having long-term stability
AssigneeMAM Holdings of West Florida, L.L.C.
InventorCarl Randall Harrell
Life of this patent
Estimating the term…
Abstract
Methods of preparing sterile de-cellularized human amniotic fluid that is amenable for long-term storage without loss of biological functions have been developed. In particular, the methods involve refrigeration steps to maximize shelf-life while retaining most of the important growth factors and other molecules present in the fresh amniotic fluid for effective therapeutic application. Use of the compositions is intended for therapeutic purposes and will alleviate pain or discomfort associated with any disorders or diseases, particularly those involving eyes and joints, or fibrotic disorders such as COPD.
Claims18
A composition consisting of sterile, de-cellularized human amniotic fluid (D-HAF) comprising a combination of growth factors, pro-inflammatory factors, and anti-inflammatory factors derived from raw amniotic fluid in an effective amount to reduce inflammation, promote wound healing, assist tissue repair, or a combination thereof,
- wherein the D-HAF is not concentrated, diluted, or heat-treated relative to the raw fluid.
A pharmaceutical composition consisting of sterile, de-cellularized human amniotic fluid (D-HAF) prepared by a process comprising de-cellularizing raw amniotic fluid to remove cells or particulate matter, wherein the D-HAF comprises a combination of growth factors, pro-inflammatory factors, and anti-inflammatory factors in an amount effective to reduce inflammation, promote wound healing, assist tissue repair, or a combination thereof, and
- pharmaceutically acceptable excipients.
Dependencies are inferred from the claim text.